ESPR - CIK 0001434868
Esperion Therapeutics, Inc. (ESPR) reported net income of -$22.68M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$22.68M | +56.2% |
| FY 2024 | -$51.74M | +75.3% |
| FY 2023 | -$209.25M | +10.4% |
| FY 2022 | -$233.66M | +13.2% |
| FY 2021 | -$269.11M | -87.5% |
| FY 2020 | -$143.55M | -47.7% |
| FY 2019 | -$97.17M | +51.9% |
| FY 2018 | -$201.81M | -20.9% |
| FY 2017 |
Esperion Therapeutics, Inc. (ESPR) reported net income of -$22.68M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, Esperion Therapeutics, Inc.'s net income declined from -$10.82M to -$22.68M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$166.99M |
| -122.7% |
| FY 2016 | -$74.98M | -50.6% |
| FY 2015 | -$49.78M | -36.9% |
| FY 2014 | -$36.38M | -39.4% |
| FY 2013 | -$26.09M | -122.2% |
| FY 2012 | -$11.74M | -8.5% |
| FY 2011 | -$10.82M | - |